{{Rsnum
|rsid=10510089
|Chromosome=10
|position=122908219
|Orientation=plus
|GMAF=0.1047
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 100.0
| HCB | 8.9 | 26.7 | 64.4
| JPT | 4.5 | 29.5 | 65.9
| YRI | 3.2 | 42.9 | 54.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 8.9 | 26.7 | 64.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10510089
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.04, combined P value= 8.15E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470181
}}

{{PMID Auto
|PMID=17903295
|Title=Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10510089
|overall_frequency_n=10
|overall_frequency_d=128
|overall_frequency=0.078125
|n_genomes=9
|n_genomes_annotated=0
|n_haplomes=11
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=2
|webscore=N
|n_web_uneval=4
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}